SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Bristol-Myers Highlights Blood Cancer Programs at ASH 2026

Bristol-Myers said its CELMoD programs are advancing across multiple myeloma and lymphoma. The body mentions Phase 3 readouts for ZENBEXUS but is truncated.

BMY

Related stories